Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases

BMC Cancer

Eliza A Hawkes¹  George Ladas²  David Cunningham¹  Andrew G Nicholson⁴  Katharina Wassilew⁴  Yolanda Barbachano³  Gihan Ratnayake¹  Sheela Rao¹  Ian Chau¹ 

[1] Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK SM2 5PT

[2] Department of Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, UK

[3] Department of Clinical Research and Development, Royal Marsden Hospital, London and Surrey, UK

[4] Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Division, Imperial College, London, UK

关键词: peri-operative chemotherapy;    lung resection;    Colorectal cancer;   

Others  :  1080282
DOI  :  10.1186/1471-2407-12-326

 received in 2012-05-04, accepted in 2012-07-17,  发布年份 2012

【 摘 要 】

Background

Surgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing pulmonary metastasectomy.

Methods

Patients treated for CRC who underwent pulmonary metastasectomy by a single surgeon were identified. Outcome measures included survival, peri-operative complications, radiological and histological evidence of chemotherapy-induced lung toxicities.

Results

Between 1997 and 2009, 51 eligible patients were identified undergoing a total of 72 pulmonary resections. Thirty-eight patients received peri-operative chemotherapy, of whom 9 received an additional biological agent. Five-year overall survival rate was 72% in the whole cohort - 74% and 68% in those who received peri-operative chemotherapy (CS) and those who underwent surgery alone (S) respectively. Five-year relapse free survival rate was 31% in the whole cohort - 38% and ≤18% in CS and S groups respectively. Only 8% had disease progression during neoadjuvant chemotherapy. There were no post-operative deaths. Surgical complications occurred in only 4% of patients who received pre-operative chemotherapy. There was neither radiological nor histological evidence of lung toxicity in resected surgical specimens.

Conclusions

Peri-operative chemotherapy can be safely delivered to CRC patients undergoing pulmonary metastasectomy. Survival in this selected group of patients was favourable.

【 授权许可】

   
2012 Hawkes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 12:2893-2917.
• [2]Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, et al.: NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Cancer Netw 2009, 7(8):778-831.
• [3]Pfannschmidt J, Hoffmann H, Dienemann H: Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol 2010, 5(6 Suppl 2):S172-S178.
• [4]Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol Off J Am Soc Clin Oncol 2008, 26(35):5721-5727.
• [5]McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC: Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992, 53(5):780-785. discussion 785–786
• [6]Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, et al.: Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004, 78(1):238-244.
• [7]Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K, Shim YM: Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007, 22(6):699-704.
• [8]Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006, 82(1):254-260.
• [9]Rama N, Monteiro A, Bernardo JE, Eugenio L, Antunes MJ: Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg 2009, 35(3):444-449.
• [10]Welter S, Jacobs J, Krbek T, Poettgen C, Stamatis G: Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg 2007, 31(2):167-172.
• [11]Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
• [12]Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009, 101(7):1033-1038.
• [13]Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, et al.: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncology Off J Eur Soc Med Oncol / ESMO 2011, 22(9):2042-2048.
• [14]Folprecht G, Gruenberger T, Bechstein W, Lordick F, Lang H, Weitz J, Suedhoff T, Hartmann JT, Liersch T, Kohne C-H: Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study. J Clin Oncol 2012, 30(suppl 4):abstr 540.
• [15]Negri F, Musolino A, Cunningham D, Pastorino U, Ladas G, Norman AR: Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy. Clin Colorectal Cancer 2004, 4(2):101-106.
• [16]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
• [17]Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
• [18]Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002, 124(5):1007-1013.
• [19]Maeda R, Isowa N, Onuma H, Miura H, Harada T, Touge H, Tokuyasu H, Kawasaki Y: Pulmonary resection for metastases from colorectal carcinoma. Interact Cardiovasc Thorac Surg 2009, 9(4):640-644.
• [20]Kanemitsu Y, Kato T, Hirai T, Yasui K: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004, 91(1):112-120.
• [21]Pfannschmidt J, Dienemann H, Hoffmann H: Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007, 84(1):324-338.
• [22]Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2009, 27(5):663-671.
• [23]Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
• [24]Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249(3):420-425.
• [25]Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I: Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010, 11(3):241-248.
• [26]Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
• [27]Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, et al.: Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol Off J Am Soc Clin Oncol 2010, 28(5):859-865.
• [28]Chun YS, Laurent A, Maru D, Vauthey JN: Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10(3):278-286.
• [29]Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano Y, Chau I: The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol Off J Eur Soc Med Oncol / ESMO 2010, 21(5):1013-1019.